Open Access

China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design

Liping Liu, Yilong Wang, Xuewei Xie, Dacheng Liu, Aili Wang, Penglian Wang, Suwen Shen, Chongke Zhong, Yufei Wei, Tan Xu, Yuesong Pan, Yong Jiang, Xia Meng, David Wang, Yonghong Zhang, Jiang He, Yongjun Wang
DOI: 10.1136/svn-2020-000828 Published 28 June 2021
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

No eLetters have been published for this article.
Back to top
Email
Print
Alerts
Citation Tools
Cite This
Download PDF

China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design
Liping Liu, Yilong Wang, Xuewei Xie, Dacheng Liu, Aili Wang, Penglian Wang, Suwen Shen, Chongke Zhong, Yufei Wei, Tan Xu, Yuesong Pan, Yong Jiang, Xia Meng, David Wang, Yonghong Zhang, Jiang He, Yongjun Wang
Stroke and Vascular Neurology Jun 2021, 6 (2) 286-290; DOI: 10.1136/svn-2020-000828
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article